ClinicalTrials.gg
Not yet recruitingNCT07538284MIDDIESUpdated Apr 20, 2026

MInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES)

A Phase 2/3 interventional study of Dexmedetomidine and Placebo in Major Abdominal Surgery, Postoperative Delirium (POD) and Sleep Disturbances, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Not yet recruiting. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies testing dexmedetomidine in Emergence Delirium — 31 open to participants now, 32 under way, 2 of them phase 3. Dexmedetomidine · Emergence Delirium.

Planned enrollment
10th of 83
400 · median 100
Started
2026
with 15 others
Phase 2/3
5 of 83
2 open now
Primary completion
2026-12
later than 18 of 31 live
Registered
62nd of 83
by date

Among the 83 studies testing dexmedetomidine in Emergence Delirium, this one is the 10th largest by planned enrollment, is one of 16 that started in 2026, is one of 5 in phase 2/3, reaches primary completion later than 18 of the 31 other live ones, and was the 62nd registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

31 of the 83 studies testing dexmedetomidine in Emergence Delirium are open now, in 10 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing dexmedetomidine in Emergence Delirium, or all of them as a file.
02

Study summary

This study aims to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patients.

Read the detailed description

Delirium is an acute, short-term brain dysfunction characterized by fluctuating consciousness, cognitive decline, inattention, and sleep-wake cycle disruption. Postoperative delirium (POD), occurring predominantly within the first postoperative week (especially days 3-5 in elderly patients), affects 11-45% of older adults after major surgery. POD prolongs hospitalization, increases morbidity and mortality 5,65,6, yet its pathophysiology remains unclear, and evidence-based pharmacological prevention is lacking. Thus, effective POD prevention strategies are urgently needed.

Preoperative anxiety, a modifiable risk factor for POD, affects 11-80% of surgical patients. It contributes to sleep disturbances (e.g., insomnia, early awakening), which may exacerbate POD via neuroendocrine and immune dysregulation. However, benzodiazepines (e.g., lorazepam, diazepam, midazolam), though effective anxiolytics, increase delirium risk and are contraindicated preoperatively per current guidelines.

Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist, induces physiological non-REM sleep without respiratory depression or hemodynamic instability. Its nasal formulation offers high bioavailability (82%), ease of administration, and is approved in China for preoperative sedation/anxiety. While intravenous (IV) DEX reduces POD in predominant ICU settings, its use in general wards remains unexplored. Preclinical studies suggest DEX enhances glymphatic clearance and exerts anti-inflammatory effects, potentially mitigating the development of POD. This study thus hypothesize that a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patient population. We set to demonstrate that to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in older patients undergoing major abdominal surgery.

03

Conditions studied

  • Major Abdominal Surgery
  • Postoperative Delirium (POD)
  • Sleep Disturbances
  • Intranasal Dexmedetomidine

Browse trials for

Keywords

  • dexmedetomidine
  • intranasal administration
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 65-90 years
  • Scheduled for a major abdominal surgery with estimated surgery time ≥ 2 hours

Exclusion criteria

Exclusion Criteria:

  • Blind, deafness or the inability to speak mandarin
  • Allergy to dexmedetomidine.
  • Renal and liver failure requiring dialysis or score > 5
  • Follow-up difficulties (i.e. active substance abuse, psychotic disorder, homelessness)
  • Previous major abdominal or cardiac surgery within 1 year of surgical procedure
  • Chronic therapy with benzodiazepines and/or antipsychotics. Severe deficit due to structural or anoxic brain damage
  • Body weight \< 35 kg
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Intranasal dexmedetomidine (100 µg total: 4 sprays, 25 µg/spray; Hengrui Medicine, China) self-administered preoperatively (\~9 PM) and optionally on the night of surgery (patient decides dose: 0, 2 sprays, or 4 sprays).

  • DrugPlacebo

    Intranasal water for injection (4 sprays, identical volume as nasal dexmedetomidine; Hengrui Medicine, China) self-administered preoperatively (\~9 PM) and optionally on the night of surgery (patient decides dose: 0, 2 sprays, or 4 sprays).

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative delirium

    Confusion Assessment Method

    Time frame: Up to postoperative day (POD) 7 or discharge (whichever first).

Secondary outcomes

  1. Delirium severity

    Confusion Assessment Method Score

    Time frame: Up to postoperative day (POD) 7 or discharge (whichever first)

  2. Physical activity

    Fitbit Flex2 tracker

    Time frame: Up to postoperative day (POD) 3

  3. Sleep quality

    Fitbit Flex2 tracker and Athens Insomnia Scale

    Time frame: Up to postoperative day (POD) 3

  4. Anxiety

    Hamilton Anxiety Scale

    Time frame: Up to postoperative day (POD) 3

  5. Pain intensity

    Numerical Rating Scale

    Time frame: Up to postoperative day (POD) 3

  6. Opioid consumption

    Intravenous morphine equivalents

    Time frame: Up to postoperative day (POD) 3

  7. Health related quality of life

    Health related quality of life assessed with the SF-36 health survey

    Time frame: On postoperative day (POD) 3 and 30

  8. Quality of Recovery

    The Quality of Recovery-15 questionnaire

    Time frame: Up to postoperative day (POD) 3

  9. Postoperative Nausea and Vomiting

    Postoperative Nausea and Vomiting Scale

    Time frame: Up to postoperative day (POD) 3

  10. Post-anesthesia Care Unit (PACU) length of stay

    Post-anesthesia Care Unit (PACU) length of stay

    Time frame: Up to postoperative day (POD) 1

Other outcomes

  1. Optional intranasal administration on the night of surgery

    Optional intranasal administration of the same spray (patient decides dose: 0, 2 sprays, or 4 sprays)

    Time frame: At night of the surgery

  2. Length of Hospital Stay

    Medical Record Review

    Time frame: From postoperative day 0 until date of hospital discharge (Up to 30 days)

  3. Cognitive function

    Abbreviated Mental Test Score

    Time frame: Up to postoperative day (POD) 30

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified data and a data dictionary will be made available upon reasonable request to researchers who provide a methodologically sound proposal and whose use of the data has been approved the study authors. Data will be made available immediately following publication, with no anticipated end date, to achieve the aims specified in the approved proposal. Proposals should be directed to ruanxc@mail.sysu.edu.cn.

Supporting information: Study protocol, Informed consent form

Time frame: Immediately

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Dec 2026, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Apr 20, 2026
StartEst.
May 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07538284
Responsible party
Xiangcai Ruan, MD, PhD (Professor, Sixth Affiliated Hospital, Sun Yat-sen University) — Principal investigator
First posted
Apr 20, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Apr 20, 2026

Study contacts

Mentying Ding, MD.
Contact
15170375679@163.com
+86-15170375679

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion